Strategic Report Governance Financial Statements Other Information Other financial information Non GAAP measures Free cash flow represents net cash provided by operating These Non GAAP financial measures are used by Shires activities, excluding up-front and milestone payments for inmanagement to make operating decisions because they facilitate licensed and acquired products, but including capital expenditure internal comparisons of Shires performance to historical results in the ordinary course of business.
In 2014 the receipt of the break and to competitors results.
Shires Remuneration Committee uses fee in relation to AbbVies terminated offer for Shire was excluded certain key Non GAAP measures when assessing the performance from free cash flow.
and compensation of employees, including Shires directors.
A reconciliation of Non GAAP financial measures to the most The Non GAAP measures are presented in this Annual Report directly comparable measure under US GAAP is presented on asShires management believe that they will provide investors pages 160 to 163. witha means of evaluating, and an understanding of how Shires Growth at CER, which is a Non GAAP measure, is computed by management evaluates, Shires performance and results on a restating 2015 results using average 2014 foreign exchange rates comparable basis that is not otherwise apparent on a US GAAP for the relevant period.
basis, since many non-recurring, infrequent or non-cash items thatShires management believe are not indicative of the core Average exchange rates used by Shire for the year to December performance of the business may not be excluded when preparing 31, 2015 were $1.53:1.00 and $1.11:1.00 2014: $1.65:1.00 and financial measures under US GAAP.
Average exchange rates used by Shire for Q4 2015 were $1.52:1.00 and $1.09:1.00 2014: $1.60:1.00 and These Non GAAP measures should not be considered in isolation $1.25:1.00. from, as substitutes for, or superior to financial measures prepared in accordance with US GAAP.
Non GAAP Adjusted ROIC reflects the definition used by the Company in its corporate scorecard.
This definition aims to Where applicable the following items, including their tax effect, measure true underlying economicperformance of the Company, have been excluded when calculating Non GAAP earnings for by making a number of adjustments to ROIC as derived from the both2015 and 2014, and from our Outlook: Companys Non GAAP financial results including: Amortization and asset impairments: Adding back to Non GAAP operating income all R&D expenses Intangible asset amortization and impairment charges: and and operating lease costs incurred in the period: Other than temporary impairment of investments.
Capitalizing on the Groups balance sheet historical, cumulative Acquisitions and integration activities: R&D, in process R&D and intangible asset impairment charges Up-front payments and milestones in respect of in-licensed and operating lease costs which previously have been andacquired products: expensed: Costs associated with acquisitions, including transaction Deducting from Non GAAP operating income and amortization costs, fair value adjustments on contingent consideration and charge for the above capitalized costs based on the estimated acquiredinventory: commercial lives of the relevant products: Costs associated with the integration of companies: and Excluding the income statement and balance sheet impact of non-operating assets such as surplus cash and non-strategic Noncontrolling interests in consolidated variable interest entities.
investments : and Divestments, reorganizations and discontinued operations: Taxing the resulting adjusted operating income at the underlying Gains and losses on the sale of non-core assets: Non GAAP effective tax rate.
Costs associated with restructuring and reorganization activities: Non GAAP EBITDA represents Non GAAP EBITA before depreciation Termination costs: and Income losses from discontinued operations.
Legal and litigation costs: Net legal costs related to the settlement of litigation,  and other disputes excluding internal legal team costs.
Other: Net income tax credit being income tax, interest and estimated penalties related to the settlement of certain tax positions with the Canadian revenue authorities: Costs associated with AbbVies terminated offer for Shire, including costs of employee retention awards: and Break fee received in relation to AbbVies terminated offer for Shire.
Depreciation, which is included in Cost of product sales, R&D andSG&A costs in our US GAAP results, has been separately disclosed for the presentation of 2015 and 2014 Non GAAP earnings.
Cash generation represents net cash provided by operating activities, excluding up-front and milestone payments for inlicensed and acquired products, tax and interest payments.
In2014 the receipt of the break fee in relation to AbbVies terminated offer for Shire was excluded from cash generation.
Shire Annual Report 2015 159 Other financial information continued Unaudited results for the year to December 31, 2015 Non GAAP reconciliation US GAAP Adjustments Non GAAP a b c d e f Year to December 31, 2015 $M $M $M $M $M $M $M $M Total revenues 6,416.7 6,416.7 Costs and expenses: Cost of product sales 969.0 31.1 7.1 46.1 884.7 R&D 1,564.0 643.7 14.5 21.7 884.1 SG&A 2,341.2 498.7 9.5 38.5 70.7 1,723.8 Gain on sale of product rights 14.7 14.7 Reorganization costs 97.9 97.9 Integration and acquisition costs 39.8 39.8 Depreciation 138.5 138.5 Total operating expenses 4,997.2 1,142.4 70.9 83.2 9.5 60.1 3,631.1 Operating income 1,419.5 1,142.4 70.9 83.2 9.5 60.1 2,785.6 Interest income 4.2 1.1 3.1 Interest expense 41.6 41.6 Other income expense, net 3.7 14.1 10.4 Income before income taxes and equity in losses of equity method investees 1,385.8 1,142.4 70.9 69.1 9.5 59.0 2,736.7 Income taxes 46.1 258.4 67.9 25.8 3.5 22.7 424.4 Equity in losses of equity method investees, net of tax 2.2 2.2 Income from continuing operations 1,337.5 884.0 3.0 43.3 6.0 36.3 2,310.1 Loss from discontinued operations, net of tax 34.1 34.1 2,310.1 Net income 1,303.4 884.0 3.0 77.4 6.0 36.3 2,310.1 Weighted average number of shares millions diluted 593.1 593.1 Diluted earnings per ADS 659.1 447.1 1.6 39.4 3.0 18.3 1,168.5 The following items are included in Adjustments: a Amortization and asset impairments: Impairment of SHP625 IPR&D intangible asset $467.0million, impairment of SHP608 IPR&D intangible asset $176.7million, amortization of intangible assets relating to intellectual property rights acquired $498.7million, and tax effect of adjustments: b Acquisition and integration activities: Unwind of NPS inventory fair value adjustments $29.8million, unwind of ViroPharma inventory fair value adjustments $1.3million, acquisition and integration costs primarily associated with NPS, ViroPharma, Dyax and the announced combination with Baxalta $189.7million, net credit related to the change in the fair value of contingent consideration liabilities $149.9million, and tax effect of adjustments: c Divestments, reorganizations and discontinued operations: Net gain on re-measurement of DAYTRANA contingent consideration to fair value $13.6million, gain on disposal of non-core product rights $1.1million, costs relating to the One Shire reorganization, primarily costs relating to the relocation of staff from Chesterbrook to Lexington $97.9million, gain on sale of long term investments $14.1million, tax effect of adjustments and loss from discontinued operations, net of tax $34.1million : d Legal and litigation costs: Costs related to litigation, government investigations, other disputes and external legal costs $9.5million, and tax effect of adjustments: e Other: Costs associated with AbbVies terminated offer for Shire $60.1million, interest income received in respect of cash deposited with the Canadian revenue authorities $1.1million : and f Depreciation reclassification: Depreciation of $138.5million included in Cost of product sales, R&D and SG&A for US GAAP separately disclosed for the presentation of Non GAAP earnings.
160 Shire Annual Report 2015 Strategic Report Governance Financial Statements Other Information Unaudited results for the year to December 31, 2014 Non GAAP reconciliation US GAAP Adjustments Non GAAP a b c d e f Year to December 31, 2014 $M $M $M $M $M $M $M $M Total revenues 6,022.1 6,022.1 Costs and expenses: Cost of product sales 979.3 91.9 57.1 830.3 R&D 1,067.5 190.3 12.5 24.5 840.2 SG&A 2,025.8 243.8 9.2 95.8 81.9 1,595.1 Gain on sale of product rights 88.2 88.2 Reorganization costs 180.9 180.9 Integration and acquisition costs 158.8 158.8 Depreciation 163.5 163.5 Total operating expenses 4,324.1 434.1 263.2 92.7 9.2 95.8 3,429.1 Operating income 1,698.0 434.1 263.2 92.7 9.2 95.8 2,593.0 Interest income 24.7 22.0 2.7 Interest expense 30.8 30.8 Other income expense, net 8.9 4.7 15.8 11.6 Receipt of break fee 1,635.4 1,635.4 Income before income taxes and equity in earnings of equity method investees 3,336.2 434.1 258.5 76.9 9.2 1,561.6 2,553.3 Income taxes 56.1 126.7 24.1 22.2 3.4 235.0 467.5 Equity in earnings of equity method investees, net of tax 2.7 2.7 Income from continuing operations 3,282.8 307.4 234.4 54.7 5.8 1,796.6 2,088.5 Gain from discontinued operations, net of tax 122.7 122.7 Net income 3,405.5 307.4 234.4 68.0 5.8 1,796.6 2,088.5 Weighted average number of shares millions diluted 591.3 591.3 Diluted earnings per ADS 1,728.0 155.9 118.7 34.6 3.0 911.4 1,059.6 The following items are included in Adjustments: a Amortization and asset impairments: Impairment of IPR&D intangible assets $190.3million, amortization of intangible assets relating to intellectual property rights acquired $243.8million, and tax effect of adjustments: b Acquisition and integration activities: Unwind of ViroPharma inventory fair value adjustments $91.9million, payments in respect of in-licensed and acquired products $12.5million, costs primarily associated with the acquisition and integration of ViroPharma $144.1million, net charge related to the change in fair values of contingent consideration liabilities $14.7million, gain on settlement of pre-existing relationship with an acquired business $4.7million, and tax effect of adjustments: c Divestments, reorganizations and discontinued operations: Net gain on divestment of non-core product rights and on re-measurement of DAYTRANA contingent consideration to fair value $88.2million, costs relating to the One Shire reorganization $180.9million, gain on sale of long term investments $15.8million, tax effect of adjustments and gain from discontinued operations, net of tax $122.7million : d Legal and litigation costs: Costs related to litigation, government investigations, other disputes and external legal costs $9.2million, and tax effect of adjustments: e Other: Costs associated with AbbVies terminated offer for Shire $95.8million, interest income received in respect of cash deposited with the Canadian revenue authorities $22.0million, receipt of break fee from AbbVie $1,635.4million, net income tax credit related to the settlement of certain tax positions with the Canadian revenue authorities $235.0million, and tax effect of adjustment: and f Depreciation reclassification: Depreciation of $163.5million included in Cost of product sales, R&D and SG&A for US GAAP separately disclosed for the presentation of Non GAAP earnings.
Shire Annual Report 2015 161 Other financial information continued Unaudited results for the year to December 31, 2015 and 2014 Non GAAP reconciliation The following table reconciles US GAAP net income to Non GAAP EBITDA: Year to December 31, 2015 2014 $M $M US GAAP Net Income 1,303.4 3,405.5 Deduct add back: Loss gain from discontinued operations, net of tax 34.1 122.7 Equity in losses earnings of equity method investees, net of taxes 2.2 2.7 Income taxes 46.1 56.1 Other income expense, net 3.7 8.9 Receipt of break fee 1,635.4 Interest expense 41.6 30.8 Interest income 4.2 24.7 US GAAP Operating income from continuing operations 1,419.5 1,698.0 Amortization 498.7 243.8 Depreciation 138.5 163.5 Asset impairments 643.7 190.3 Acquisition and integration activities 70.9 263.2 Divestments, reorganizations and discontinued operations 83.2 92.7 Legal and litigation costs 9.5 9.2 Other 60.1 95.8 Non GAAP EBITDA 2,924.1 2,756.5 Depreciation 138.5 163.5 Non GAAP Operating income from continuing operations 2,785.6 2,593.0 1 Net income margin 20% 57% 2 Non GAAP EBITDA margin 43% 44% 1 Net income as a percentage of total revenues.
2 Non GAAP EBITDA as a percentage of product sales, excluding royalties and other revenues.
Unaudited results for the year to December 31, 2015 and 2014 Non GAAP reconciliation The following table reconciles US GAAP product sales to Non GAAP Gross Margin: Year to December 31, 2015 2014 $M $M US GAAP Product Sales 6,099.9 5,830.4 Deduct add back: Cost of product sales US GAAP 969.0 979.3 Unwind of inventory fair value step-up 31.1 91.9 Costs of employee retention awards following AbbVies terminated offer for Shire 7.1 Depreciation 46.1 57.1 Non GAAP Gross Margin 5,215.2 5,000.1 1 Non GAAP Gross Margin % 85.5% 85.8% 1 Gross Product Margin as a percentage of product sales.
162 Shire Annual Report 2015 Strategic Report Governance Financial Statements Other Information The following table reconciles US GAAP net cash provided by operating activities to Non GAAP cash generation: Year to December 31, 2015 2014 $M $M Net cash provided by operating activities 2,337.0 4,228.4 Tax and interest payments, net 85.2 213.0 Receipt from the Canadian revenue authorities 417.0 Up-front payments in respect of in-licensed and acquired products 12.5 Receipt of break fee 1,635.4 Non GAAP cash generation 2,422.2 2,401.5 The following table reconciles US GAAP net cash provided by operating activities to Non GAAP free cash flow: Year to December 31, 2015 2014 $M $M Net cash provided by operating activities 2,337.0 4,228.4 Up-front payments in respect of in-licensed and acquired products 12.5 Capital expenditure 114.7 77.0 Receipt of break fee 1,635.4 Non GAAP free cash flow 2,222.3 2,528.5 Non GAAP net debt cash comprises: December 31, December 31, 2015 2014 $M $M Cash and cash equivalents 135.5 2,982.4 Long term borrowings 69.9 Short term borrowings 1,511.5 850.0 Other debt 13.4 13.7 Non GAAP net debt cash 1,459.3 2,118.7 Shire Annual Report 2015 163
